Parkinson Disease (autosomal Dominant Uses, Dosage, Side Effects and more
Parkinson Disease (autosomal Dominant is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
| Trade Name | Parkinson Disease (autosomal Dominant |
| Generic | Cinpanemab |
| Cinpanemab Other Names | Cinpanemab, Immunoglobulin g1-lambda, anti-(homo sapiens alpha-synuclein)humanized monoclonal antibody.gamma.1 heavy chain (1-442) (homo sapiens vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo sapiens ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-, Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo, Immunoglobulin g1, anti-(human .alpha.-synuclein) (human monoclonal biib054 .gamma.1-chain), disulfide with human monoclonal biib054 .kappa.-chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
